Pap Technology Wars Expected to Intensify

Digene’s blood-based HPV assay produces more favorable data with latest trial results

CEO SUMMARY: With patience and persistence, Digene, Inc. is developing the effectiveness of its DNA-based HPV assay. Publication of recently-completed clinical trials provides evidence that Digene’s Hybrid Capture II ® HPV test, with further improvement, might become a relevant tool in the diagnostic pathway for cervical cancer. It’s another new technology with the potential to

Subscriber-Only Content. Please Log In.

You are trying to access subscribers-only content. If you are a subscriber, please log in.

If you are not a subscriber, click here to see subscription offers.

Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!

To read our FREE article previews, go to The Dark Report Insider.

Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Enter Your Login Credentials
×